Quarterly report pursuant to Section 13 or 15(d)

Note 4 - Fair Value Measurements (Details Textual)

v3.8.0.1
Note 4 - Fair Value Measurements (Details Textual) - USD ($)
$ in Millions
3 Months Ended
Sep. 30, 2017
Jun. 30, 2017
Aug. 01, 2016
Mar. 14, 2016
Nov. 03, 2014
Advanced Cell Diagnostics (ACD) [Member]          
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High $ 75.0 $ 50.0      
Business Combination, Liabilities Arising from Contingencies, Amount Recognized     $ 37.0    
Zephyrus [Member]          
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High 7.0 3.5      
Business Combination, Liabilities Arising from Contingencies, Amount Recognized       $ 6.5  
CyVek, Inc. [Member]          
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High 35.0 $ 35.0      
Business Combination, Liabilities Arising from Contingencies, Amount Recognized         $ 35.0
Payment for Contingent Consideration Liability 35.0        
Advance Cell Diagnostics (ACD), Zephyrus, and CyVek Inc.[Member]          
Business Combination, Liabilities Arising from Contingencies, Amount Recognized $ 78.5